Clinical evidence dossier
Mediterranean diet
HbA1c
Evidence signal
Evidence signal
Strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 7
- Supporting studies available for review
- 7
- Randomized trials
- 7
- Reported effects
- 7
Clinical conclusion
Mediterranean diet shows a moderate positive evidence signal for improving HbA1c across the studied comparisons.
The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
−0.67% to 0.39%
Between-group effect
Absolute change
−0.7% to −0.1%
Between-group effect
Mean difference
−0.39% to −0.39%
Between-group effect
Mean difference
−4 mmol/mol to −3 mmol/mol
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 0
- Magnitude-eligible effects
- 7
Consistency
Consistency classification
Mostly consistent
- Positive
- 4
- No effect
- 3
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 7 of 7 supporting studies. Diabetes type was heterogeneous: 5 studies with type 2 diabetes, 1 studies with type 1 diabetes. 5 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Older adults aged 65 and above.
- Individuals diagnosed with Type 2 diabetes.
- Youths with varying levels of diabetes management experience.
- Adults diagnosed with type 2 diabetes.
- Individuals seeking nonpharmacological dietary interventions.
- 8-12 gestational weeks
- normoglycemic fasting glucose <92 mg/dL at enrollment
- <92
- reported in discussion as mean BMI <25 kg/m2
- Adults diagnosed with Type 2 Diabetes Mellitus.
- Individuals experiencing daytime sleepiness.
- Adults with newly diagnosed type 2 diabetes.
Limitations
- 3 supporting studies do not have a displayable topic-matched quantitative effect.
- Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, other, usual_care.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.